Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts

Alzheimer's Disease Neuroimaging Initiative, Alzheimer’s Disease Metabolomics Consortium

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Alzheimer’s disease (AD) is the most common cause of dementia. The mechanism of disease development and progression is not well understood, but increasing evidence suggests multifactorial etiology, with a number of genetic, environmental, and aging-related factors. There is a growing body of evidence that metabolic defects may contribute to this complex disease. To interrogate the relationship between system level metabolites and disease susceptibility and progression, the AD Metabolomics Consortium (ADMC) in partnership with AD Neuroimaging Initiative (ADNI) is creating a comprehensive biochemical database for patients in the ADNI1 cohort. We used the Biocrates Bile Acids platform to evaluate the association of metabolic levels with disease risk and progression. We detail the quantitative metabolomics data generated on the baseline samples from ADNI1 and ADNIGO/2 (370 cognitively normal, 887 mild cognitive impairment, and 305 AD). Similar to our previous reports on ADNI1, we present the tools for data quality control and initial analysis. This data descriptor represents the third in a series of comprehensive metabolomics datasets from the ADMC on the ADNI.

Original languageEnglish (US)
Article number212
JournalScientific Data
Issue number1
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Information Systems
  • Education
  • Library and Information Sciences
  • Statistics and Probability
  • Computer Science Applications
  • Statistics, Probability and Uncertainty


Dive into the research topics of 'Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts'. Together they form a unique fingerprint.

Cite this